AR036877A1 - Formulacion farmaceutica - Google Patents

Formulacion farmaceutica

Info

Publication number
AR036877A1
AR036877A1 ARP020103826A ARP020103826A AR036877A1 AR 036877 A1 AR036877 A1 AR 036877A1 AR P020103826 A ARP020103826 A AR P020103826A AR P020103826 A ARP020103826 A AR P020103826A AR 036877 A1 AR036877 A1 AR 036877A1
Authority
AR
Argentina
Prior art keywords
drug
pharmaceutical formulation
enantiomer
increase
solid dispersion
Prior art date
Application number
ARP020103826A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astra Zeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Zeneca Uk Ltd filed Critical Astra Zeneca Uk Ltd
Publication of AR036877A1 publication Critical patent/AR036877A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulación farmacéutica que comprende el fármaco 4'-ciano-a', a', a'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidroxi-2-metilpropion-m-toluidida en una dispersión sólida con un polímero entérico que posee un valor de pKa entre 3 y6 , donde >50% del fármaco se provee en la forma del enantiómero R . Dosis farmacéutica diaria del fármaco provista por dicha formulación. El uso de un polímero entérico que posee un valor de pKa entre 3 y 6 en dispersión sólida con el fármaco, donde >50% del fármaco se provee en la forma del enantiómero R, para incrementar la biodisponibilidad del fármaco; para reducir la variabilidad entre pacientes en cuanto a las concentraciones del fármaco; para aumentar la estabilidad al almacenamiento del fármaco; o para tratar y/o reducir el riesgo de padecer cáncer de próstata en un paciente.
ARP020103826A 2001-10-15 2002-10-11 Formulacion farmaceutica AR036877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103424A SE0103424D0 (sv) 2001-10-15 2001-10-15 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AR036877A1 true AR036877A1 (es) 2004-10-13

Family

ID=20285650

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103826A AR036877A1 (es) 2001-10-15 2002-10-11 Formulacion farmaceutica

Country Status (19)

Country Link
US (1) US20060058381A1 (es)
EP (1) EP1439823A1 (es)
JP (1) JP3639587B2 (es)
KR (1) KR20050035163A (es)
CN (1) CN1571658A (es)
AR (1) AR036877A1 (es)
BR (1) BR0213248A (es)
CA (1) CA2462219A1 (es)
CO (1) CO5580755A2 (es)
HU (1) HUP0401369A3 (es)
IL (1) IL161306A0 (es)
IS (1) IS7219A (es)
MX (1) MXPA04003520A (es)
NO (1) NO20041485L (es)
PL (1) PL368226A1 (es)
RU (1) RU2004115023A (es)
SE (1) SE0103424D0 (es)
WO (1) WO2003032950A1 (es)
ZA (1) ZA200402729B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365746A1 (en) * 2001-02-27 2005-01-10 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
HUE039902T2 (hu) 2004-01-20 2019-02-28 Novartis Ag Közvetlenül préselt formula és eljárás
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
WO2013012959A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
MX2015012274A (es) 2013-03-14 2016-06-02 Univ Maryland Agentes de sub-regulacion del receptor de androgeno y uso de los mismos.
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CR20170218A (es) 2014-12-05 2017-08-30 Aragon Pharmaceuticals Inc Composiciones anticancerígenas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629237A (en) * 1968-09-12 1971-12-21 Shinetsu Chemical Co Compositions useful as enteric coatings and method for preparing acid phthalates of cellulose ethers for them
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
PL365746A1 (en) * 2001-02-27 2005-01-10 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
NZ528284A (en) * 2001-04-02 2005-04-29 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and PVP

Also Published As

Publication number Publication date
BR0213248A (pt) 2004-09-28
MXPA04003520A (es) 2004-07-23
IS7219A (is) 2004-04-14
HUP0401369A2 (hu) 2004-11-29
SE0103424D0 (sv) 2001-10-15
CN1571658A (zh) 2005-01-26
IL161306A0 (en) 2004-09-27
JP3639587B2 (ja) 2005-04-20
EP1439823A1 (en) 2004-07-28
US20060058381A1 (en) 2006-03-16
RU2004115023A (ru) 2005-04-10
CA2462219A1 (en) 2003-04-24
NO20041485L (no) 2004-04-13
KR20050035163A (ko) 2005-04-15
ZA200402729B (en) 2005-01-13
CO5580755A2 (es) 2005-11-30
JP2004521963A (ja) 2004-07-22
PL368226A1 (en) 2005-03-21
HUP0401369A3 (en) 2006-05-29
WO2003032950A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
UY27186A1 (es) Formulación farmacéutica
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
AR036877A1 (es) Formulacion farmaceutica
PT1411938E (pt) Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase
CR7362A (es) Formulaciones farmaceuticas de derivado de platino
AR090677A2 (es) Preparacion farmaceutica que contiene oxicodona y naloxona
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
HUP0203623A2 (hu) Tramadol-szacharinátot tartalmazó, késleltetett hatású adagolási forma és alkalmazása
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
DK1256339T3 (da) Transdermalt terapeutisk system for opnåelse af høje plasmaniveauer af rotigotin i behandlingen af Parkinsons sygdom
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
BR0311414A (pt) Agente terapêutico para uma bexiga hiperativa
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
UY27539A1 (es) Formulación farmacéutica
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ECSP056190A (es) Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen
BR0313881A (pt) Remédio
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno

Legal Events

Date Code Title Description
FB Suspension of granting procedure